{"doc_id": "33464336", "type of study": "Therapy", "title": "", "abstract": "Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial.\nImportance : It is unknown whether angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) have a positive, neutral, or negative effect on clinical outcomes in patients with coronavirus disease 2019 (COVID-19).\nObjective : To determine whether discontinuation compared with continuation of ACEIs or ARBs changed the number of days alive and out of the hospital through 30 days.\nDesign, Setting, and Participants : A randomized clinical trial of 659 patients hospitalized in Brazil with mild to moderate COVID-19 who were taking ACEIs or ARBs prior to hospitalization (enrolled: April 9-June 26, 2020; final follow-up: July 26, 2020).\nInterventions : Discontinuation (n\u2009=\u2009334) or continuation (n\u2009=\u2009325) of ACEIs or ARBs.\nMain Outcomes and Measures : The primary outcome was the number of days alive and out of the hospital through 30 days.\nSecondary outcomes included death, cardiovascular death, and COVID-19 progression.\nResults : Among 659 patients, the median age was 55.1 years (interquartile range [IQR], 46.1-65.0 years), 14.7% were aged 70 years or older, 40.4% were women, and 100% completed the trial.\nThe median time from symptom onset to hospital admission was 6 days (IQR, 4-9 days) and 27.2% of patients had an oxygen saturation of less than 94% of room air at baseline.\nIn terms of clinical severity, 57.1% of patients were considered mild at hospital admission and 42.9% were considered moderate.\nThere was no significant difference in the number of days alive and out of the hospital in patients in the discontinuation group (mean, 21.9 days [SD, 8 days]) vs patients in the continuation group (mean, 22.9 days [SD, 7.1 days]) and the mean ratio was 0.95 (95% CI, 0.90-1.01).\nThere also was no statistically significant difference in death (2.7% for the discontinuation group vs 2.8% for the continuation group; odds ratio [OR], 0.97 [95% CI, 0.38-2.52]), cardiovascular death (0.6% vs 0.3%, respectively; OR, 1.95 [95% CI, 0.19-42.12]), or COVID-19 progression (38.3% vs 32.3%; OR, 1.30 [95% CI, 0.95-1.80]).\nThe most common adverse events were respiratory failure requiring invasive mechanical ventilation (9.6% in the discontinuation group vs 7.7% in the continuation group), shock requiring vasopressors (8.4% vs 7.1%, respectively), acute myocardial infarction (7.5% vs 4.6%), new or worsening heart failure (4.2% vs 4.9%), and acute kidney failure requiring hemodialysis (3.3% vs 2.8%).\nConclusions and Relevance : Among patients hospitalized with mild to moderate COVID-19 and who were taking ACEIs or ARBs before hospital admission, there was no significant difference in the mean number of days alive and out of the hospital for those assigned to discontinue vs continue these medications.\nThese findings do not support routinely discontinuing ACEIs or ARBs among patients hospitalized with mild to moderate COVID-19 if there is an indication for treatment.\nTrial Registration : ClinicalTrials.gov Identifier: NCT04364893.\n", "Evidence Map": {"Enrollment": [{"term": "Admitted", "negation": "affirmed", "UMLS": {}, "start": 166, "end": 174}, {"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 180, "end": 188}, {"term": "hospitalized", "negation": "affirmed", "UMLS": {}, "start": 82, "end": 94}, {"term": "mild to moderate COVID-19", "negation": "affirmed", "UMLS": {}, "start": 110, "end": 135}, {"term": "ACEIs or ARBs prior to hospitalization", "negation": "affirmed", "UMLS": {}, "start": 152, "end": 190}, {"term": "hospitalized", "negation": "affirmed", "UMLS": {}, "start": 43, "end": 55}, {"term": "mild to moderate COVID-19", "negation": "affirmed", "UMLS": {}, "start": 61, "end": 86}, {"term": "ACEIs or ARBs", "negation": "affirmed", "UMLS": {}, "start": 107, "end": 120}, {"term": "hospital admission", "negation": "affirmed", "UMLS": {}, "start": 128, "end": 146}, {"term": "hospitalized", "negation": "negated", "UMLS": {}, "start": 83, "end": 95}, {"term": "mild to moderate COVID-19", "negation": "negated", "UMLS": {}, "start": 101, "end": 126}], "Comparison Results": [], "Study Arm 1 Results": [], "Study Arm 2 Results": [], "Hypothesis": []}, "Sentence-level breakdown": [{"Section": "TITLE", "Text": "Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19 : A Randomized Clinical Trial .", "Evidence Elements": {"Participant": [{"term": "Admitted", "negation": "affirmed", "UMLS": {}, "start": 166, "end": 174}, {"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 180, "end": 188}], "Intervention": [{"term": "Discontinuing", "negation": "affirmed", "UMLS": {}, "start": 10, "end": 23, "has_relation": "N/A"}, {"term": "Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers", "negation": "affirmed", "UMLS": {}, "start": 27, "end": 115, "has_chemical": [{"text": "angiotensin", "maps_to": "C0003018:angiotensins", "start": 11, "end": 22}, {"text": "enzyme inhibitors", "maps_to": "C0014432:enzyme inhibitors", "start": 34, "end": 51}, {"text": "angiotensin ii receptor", "maps_to": "C0003011:angiotensin ii receptor", "start": 56, "end": 79}], "has_relation": "N/A"}], "Outcome": [{"term": "Days Alive", "negation": "affirmed", "UMLS": {}, "start": 119, "end": 129}, {"term": "Out of the Hospital", "negation": "affirmed", "UMLS": {}, "start": 134, "end": 153}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Importance : It is unknown whether angiotensin-converting enzyme inhibitors ( ACEIs ) or angiotensin II receptor blockers ( ARBs ) have a positive , neutral , or negative effect on clinical outcomes in patients with coronavirus disease 2019 ( COVID-19 ) .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "clinical outcomes", "negation": "affirmed", "UMLS": {}, "start": 181, "end": 198}], "Observation": [{"term": "positive", "negation": "affirmed", "UMLS": {}, "start": 138, "end": 146}, {"term": "effect", "negation": "affirmed", "UMLS": {}, "start": 171, "end": 177}], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Objective : To determine whether discontinuation compared with continuation of ACEIs or ARBs changed the number of days alive and out of the hospital through 30 days .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "discontinuation", "negation": "affirmed", "UMLS": {}, "start": 33, "end": 48, "has_procedure": [{"text": "discontinuation", "maps_to": "C4552847:discontinuation", "start": 0, "end": 15}], "has_relation": "N/A"}, {"term": "continuation of ACEIs or ARBs", "negation": "affirmed", "UMLS": {}, "start": 63, "end": 92, "has_chemical": [{"text": "angiotensin", "maps_to": "C0003018:angiotensins", "start": 16, "end": 27}, {"text": "enzyme inhibitors", "maps_to": "C0014432:enzyme inhibitors", "start": 39, "end": 56}, {"text": "angiotensin ii receptor", "maps_to": "C0003011:angiotensin ii receptor", "start": 60, "end": 83}], "has_relation": "N/A"}], "Outcome": [{"term": "number of days alive and out of the hospital", "negation": "affirmed", "UMLS": {}, "start": 105, "end": 149}], "Observation": [{"term": "changed", "negation": "affirmed", "UMLS": {}, "start": 93, "end": 100}], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Design , Setting , and Participants : A randomized clinical trial of 659 patients hospitalized in Brazil with mild to moderate COVID-19 who were taking ACEIs or ARBs prior to hospitalization ( enrolled : April 9-June 26 , 2020 ; final follow-up : July 26 , 2020 ) .", "Evidence Elements": {"Participant": [{"term": "hospitalized", "negation": "affirmed", "UMLS": {}, "start": 82, "end": 94}, {"term": "mild to moderate COVID-19", "negation": "affirmed", "UMLS": {}, "start": 110, "end": 135}, {"term": "ACEIs or ARBs prior to hospitalization", "negation": "affirmed", "UMLS": {}, "start": 152, "end": 190}], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Interventions : Discontinuation ( n = 334 ) or continuation ( n = 325 ) of ACEIs or ARBs .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "Discontinuation", "negation": "affirmed", "UMLS": {}, "start": 16, "end": 31, "has_procedure": [{"text": "discontinuation", "maps_to": "C4552847:discontinuation", "start": 0, "end": 15}], "has_relation": "N/A"}, {"term": "continuation", "negation": "affirmed", "UMLS": {}, "start": 19, "end": 31, "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Main Outcomes and Measures : The primary outcome was the number of days alive and out of the hospital through 30 days .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "number of days alive and out of the hospital", "negation": "affirmed", "UMLS": {}, "start": 57, "end": 101}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Secondary outcomes included death , cardiovascular death , and COVID-19 progression .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "death", "negation": "affirmed", "UMLS": {}, "start": 28, "end": 33}, {"term": "cardiovascular death", "negation": "affirmed", "UMLS": {}, "start": 36, "end": 56}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Results : Among 659 patients , the median age was 55.1 years ( interquartile range [ IQR ] , 46.1-65.0 years ) , 14.7 % were aged 70 years or older , 40.4 % were women , and 100 % completed the trial .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "The median time from symptom onset to hospital admission was 6 days (IQR , 4-9 days ) and 27.2 % of patients had an oxygen saturation of less than 94 % of room air at baseline .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "median time from symptom onset to hospital admission", "negation": "affirmed", "UMLS": {}, "start": 4, "end": 56}, {"term": "oxygen saturation of less than 94 % of", "negation": "affirmed", "UMLS": {}, "start": 116, "end": 154}], "Observation": [{"term": "6 days", "negation": "affirmed", "UMLS": {}, "start": 61, "end": 67}], "Count": [{"term": "27.2 %", "negation": "affirmed", "UMLS": {}, "start": 90, "end": 96}, {"term": "patients", "negation": "affirmed", "UMLS": {}, "start": 100, "end": 108}]}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "In terms of clinical severity , 57.1 % of patients were considered mild at hospital admission and 42.9 % were considered moderate .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "mild at hospital admission", "negation": "affirmed", "UMLS": {}, "start": 67, "end": 93, "has_procedure": [{"text": "hospital admission", "maps_to": "C0184666:hospital admission", "start": 8, "end": 26}], "has_relation": "N/A"}], "Outcome": [{"term": "clinical severity", "negation": "affirmed", "UMLS": {}, "start": 12, "end": 29}], "Observation": [], "Count": [{"term": "57.1 %", "negation": "affirmed", "UMLS": {}, "start": 32, "end": 38}, {"term": "patients", "negation": "affirmed", "UMLS": {}, "start": 42, "end": 50}, {"term": "42.9 %", "negation": "affirmed", "UMLS": {}, "start": 98, "end": 104}]}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "There was no significant difference in the number of days alive and out of the hospital in patients in the discontinuation group ( mean , 21.9 days [ SD , 8 days ] ) vs patients in the continuation group ( mean , 22.9 days [ SD , 7.1 days ] ) and the mean ratio was 0.95 ( 95 % CI , 0.90-1.01 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "discontinuation", "negation": "negated", "UMLS": {}, "start": 107, "end": 122, "has_procedure": [{"text": "discontinuation", "maps_to": "C4552847:discontinuation", "start": 0, "end": 15}], "has_relation": "N/A"}, {"term": "continuation", "negation": "negated", "UMLS": {}, "start": 110, "end": 122, "has_relation": "N/A"}], "Outcome": [{"term": "number of days alive and out of the hospital", "negation": "negated", "UMLS": {}, "start": 43, "end": 87}], "Observation": [{"term": "significant difference", "negation": "affirmed", "UMLS": {}, "start": 13, "end": 35}], "Count": []}, "Evidence Propositions": [{"Intervention": [{"term": "discontinuation", "has_procedure": [{"text": "discontinuation", "maps_to": "C4552847:discontinuation", "start": 0, "end": 15}], "has_relation": "N/A"}, {"term": "continuation", "has_relation": "N/A"}], "Observation": "significant difference", "Outcome": "number of days alive and out of the hospital", "Count": ""}]}, {"Section": "UNKNOWN", "Text": "There also was no statistically significant difference in death ( 2.7 % for the discontinuation group vs 2.8 % for the continuation group ; odds ratio [ OR ] , 0.97 [ 95 % CI , 0.38-2.52 ] ) , cardiovascular death ( 0.6 % vs 0.3 % , respectively ; OR , 1.95 [ 95 % CI , 0.19-42.12 ] ) , or COVID-19 progression ( 38.3 % vs 32.3 % ; OR , 1.30 [ 95 % CI , 0.95-1.80 ] ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "discontinuation", "negation": "negated", "UMLS": {}, "start": 80, "end": 95, "has_procedure": [{"text": "discontinuation", "maps_to": "C4552847:discontinuation", "start": 0, "end": 15}], "has_relation": "N/A"}, {"term": "continuation", "negation": "negated", "UMLS": {}, "start": 83, "end": 95, "has_relation": "N/A"}], "Outcome": [{"term": "death", "negation": "negated", "UMLS": {}, "start": 58, "end": 63}, {"term": "cardiovascular death", "negation": "negated", "UMLS": {}, "start": 193, "end": 213}], "Observation": [{"term": "statistically significant difference", "negation": "negated", "UMLS": {}, "start": 18, "end": 54}, {"term": "2.7 %", "negation": "affirmed", "UMLS": {}, "start": 66, "end": 71}, {"term": "2.8 %", "negation": "affirmed", "UMLS": {}, "start": 105, "end": 110}, {"term": "0.6 %", "negation": "affirmed", "UMLS": {}, "start": 216, "end": 221}, {"term": "0.3 %", "negation": "affirmed", "UMLS": {}, "start": 225, "end": 230}], "Count": []}, "Evidence Propositions": [{"Intervention": [], "Observation": "statistically significant difference", "Outcome": "death", "Count": ""}, {"Intervention": {"term": "discontinuation", "has_procedure": [{"text": "discontinuation", "maps_to": "C4552847:discontinuation", "start": 0, "end": 15}], "has_relation": "N/A"}, "Observation": "2.7 %", "Outcome": "death", "Count": ""}, {"Intervention": {"term": "continuation", "has_relation": "N/A"}, "Observation": "2.8 %", "Outcome": "death", "Count": ""}, {"Intervention": {"term": "discontinuation", "has_procedure": [{"text": "discontinuation", "maps_to": "C4552847:discontinuation", "start": 0, "end": 15}], "has_relation": "N/A"}, "Observation": "0.6 %", "Outcome": "cardiovascular death", "Count": ""}, {"Intervention": {"term": "continuation", "has_relation": "N/A"}, "Observation": "0.3 %", "Outcome": "cardiovascular death", "Count": ""}]}, {"Section": "UNKNOWN", "Text": "The most common adverse events were respiratory failure requiring invasive mechanical ventilation ( 9.6 % in the discontinuation group vs 7.7 % in the continuation group ) , shock requiring vasopressors ( 8.4 % vs 7.1 % , respectively ) , acute myocardial infarction ( 7.5 % vs 4.6 % ) , new or worsening heart failure ( 4.2 % vs 4.9 % ) , and acute kidney failure requiring hemodialysis ( 3.3 % vs 2.8 % ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "discontinuation", "negation": "affirmed", "UMLS": {}, "start": 113, "end": 128, "has_procedure": [{"text": "discontinuation", "maps_to": "C4552847:discontinuation", "start": 0, "end": 15}], "has_relation": "N/A"}, {"term": "continuation", "negation": "affirmed", "UMLS": {}, "start": 116, "end": 128, "has_relation": "N/A"}], "Outcome": [{"term": "respiratory failure requiring invasive mechanical ventilation", "negation": "affirmed", "UMLS": {}, "start": 36, "end": 97}, {"term": "shock requiring vasopressors", "negation": "affirmed", "UMLS": {}, "start": 174, "end": 202}, {"term": "acute myocardial infarction", "negation": "affirmed", "UMLS": {}, "start": 239, "end": 266}, {"term": "new", "negation": "affirmed", "UMLS": {}, "start": 288, "end": 291}], "Observation": [{"term": "most common", "negation": "affirmed", "UMLS": {}, "start": 4, "end": 15}, {"term": "9.6 %", "negation": "affirmed", "UMLS": {}, "start": 100, "end": 105}, {"term": "7.7 %", "negation": "affirmed", "UMLS": {}, "start": 138, "end": 143}, {"term": "8.4 %", "negation": "affirmed", "UMLS": {}, "start": 205, "end": 210}, {"term": "7.1 %", "negation": "affirmed", "UMLS": {}, "start": 214, "end": 219}, {"term": "7.5 %", "negation": "affirmed", "UMLS": {}, "start": 269, "end": 274}, {"term": "4.6 %", "negation": "affirmed", "UMLS": {}, "start": 278, "end": 283}], "Count": []}, "Evidence Propositions": [{"Intervention": [], "Observation": "most common", "Outcome": "respiratory failure requiring invasive mechanical ventilation", "Count": ""}, {"Intervention": {"term": "discontinuation", "has_procedure": [{"text": "discontinuation", "maps_to": "C4552847:discontinuation", "start": 0, "end": 15}], "has_relation": "N/A"}, "Observation": "9.6 %", "Outcome": "respiratory failure requiring invasive mechanical ventilation", "Count": ""}, {"Intervention": {"term": "continuation", "has_relation": "N/A"}, "Observation": "7.7 %", "Outcome": "respiratory failure requiring invasive mechanical ventilation", "Count": ""}, {"Intervention": {"term": "discontinuation", "has_procedure": [{"text": "discontinuation", "maps_to": "C4552847:discontinuation", "start": 0, "end": 15}], "has_relation": "N/A"}, "Observation": "8.4 %", "Outcome": "shock requiring vasopressors", "Count": ""}]}, {"Section": "UNKNOWN", "Text": "Conclusions and Relevance : Among patients hospitalized with mild to moderate COVID-19 and who were taking ACEIs or ARBs before hospital admission , there was no significant difference in the mean number of days alive and out of the hospital for those assigned to discontinue vs continue these medications .", "Evidence Elements": {"Participant": [{"term": "hospitalized", "negation": "affirmed", "UMLS": {}, "start": 43, "end": 55}, {"term": "mild to moderate COVID-19", "negation": "affirmed", "UMLS": {}, "start": 61, "end": 86}, {"term": "ACEIs or ARBs", "negation": "affirmed", "UMLS": {}, "start": 107, "end": 120}, {"term": "hospital admission", "negation": "affirmed", "UMLS": {}, "start": 128, "end": 146}], "Intervention": [{"term": "discontinue", "negation": "negated", "UMLS": {}, "start": 264, "end": 275, "has_relation": "N/A"}, {"term": "continue these", "negation": "negated", "UMLS": {}, "start": 279, "end": 293, "has_relation": "N/A"}], "Outcome": [{"term": "mean number of days alive and out of the hospital", "negation": "negated", "UMLS": {}, "start": 192, "end": 241}], "Observation": [{"term": "significant difference", "negation": "affirmed", "UMLS": {}, "start": 162, "end": 184}], "Count": []}, "Evidence Propositions": [{"Intervention": [{"term": "discontinue", "has_relation": "N/A"}, {"term": "continue these", "has_relation": "N/A"}], "Observation": "significant difference", "Outcome": "mean number of days alive and out of the hospital", "Count": ""}]}, {"Section": "UNKNOWN", "Text": "These findings do not support routinely discontinuing ACEIs or ARBs among patients hospitalized with mild to moderate COVID-19 if there is an indication for treatment .", "Evidence Elements": {"Participant": [{"term": "hospitalized", "negation": "negated", "UMLS": {}, "start": 83, "end": 95}, {"term": "mild to moderate COVID-19", "negation": "negated", "UMLS": {}, "start": 101, "end": 126}], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Trial Registration : ClinicalTrials.gov Identifier : NCT04364893 .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}]}